Programmed Cell Death 1 (PD-1) Inhibitors in Renal Transplant Patients with Advanced Cancer: A Double-Edged Sword?

Given advancements in cancer immunity, cancer treatment has gained breakthrough developments. Immune checkpoint inhibitors, such as programmed cell death 1 (PD-1) inhibitors, are the most promising drugs in the field and have been approved to treat various types of cancer, such as metastatic melanom...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Hung-Chih, Lin, Ji-Fan, Hwang, Thomas I.S., Liu, Ya-Fang, Yang, An-Hang, Wu, Chung-Kuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540260/
https://www.ncbi.nlm.nih.gov/pubmed/31058839
http://dx.doi.org/10.3390/ijms20092194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540260/
https://www.ncbi.nlm.nih.gov/pubmed/31058839
http://dx.doi.org/10.3390/ijms20092194

Ejemplares similares